FDA clearance obtained for ALE.P02, clinical trials expected to commence in Q1 2025.
Founders
Roberto Iacone
Company Description
Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for CLDN1+ tumours. The company is pioneering anti-CLDN1 ADCs and antibodies to modify and reverse the course of select diseases.
Market
Clinical-stage oncology
Location
Basel,
Switzerland
Coinvestors
Novo Holdings, Jeito Capital, Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, Avego Bioscience Capital, RA Capital Management, Morningside Venture Investments, BB Pureos, BPI France